drugset / Trial / NCT07492706
Safety, Tolerability and Immunogenicity of a Maternal Respiratory Syncytial Virus (RSV) Vaccine (MKK900) in Healthy Adult Women
RandomizedParallel-groupQuadruple-blindTreatment
Summary
A Phase 1 study to evaluate safety, tolerability and immunogenicity a RSV vaccine in healthy women 18 to 49 years of age
Timeline
- Start
- 2026-04-01
- Primary completion
- 2026-04-30
- Completion
- 2027-01-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MKK900 | Unknown | 60 ug | Intramuscular |
| Subject | MKK900 | Unknown | 120 ug | Intramuscular |
| Comparator | RSVpreF | Vaccine | 120 ug | Intramuscular |